Shen Qian, Xu Hong, Cao Qi, Zhou Li-Jun, Xu Jin, Fang Xiao-Yan, Ge Jie
Department of Nephrology and Rheumatology, Children's Hospital of Fudan University, Shanghai, China.
Pediatr Transplant. 2011 Jun;15(4):E76-9. doi: 10.1111/j.1399-3046.2010.01291.x. Epub 2010 Jan 27.
We studied a case of recurrent PV-B19-associated anemia in a renal transplant child with long-term remission induced by baseline immunosuppression adjusted and intensive IVIG therapy. This was a 15-yr-old boy. Seven wk after transplantation, he experienced acute rejection, which was treated with high-dose steroids, ATG, and plasmapheresis. Ten wk after transplantation (three wk after rejection), his hemoglobin dropped to 54 g/L and serum PV-B19 PCR was positive. After therapy with IVIG and conversion from mycophenolate mofetil to rapamycin, anemia resolved. But the patient had fever on the fourth day of IVIG with mild pulmonary edema and rise in serum creatinine. Two months after the first course of IVIG, anemia recurred and a second course of IVIG (preadministration methylprednisolone) was given, which was followed by the resolution of anemia without side effect and recurrence two months later again. Baseline immunosuppression was adjusted with dual immunosuppression and low doses including prednisolone and tacrolimus. At the same time, monthly course of IVIG was repeated four times. Within the next 23 months, anemia did not recur and renal function remained stable. In conclusion, PV-B19-associated anemia can be recurrent in immunocompromised children and baseline immunosuppression should be carefully adjusted to control PV-B19 infection.
我们研究了一例肾移植儿童复发性细小病毒B19相关性贫血,通过调整基线免疫抑制和强化静脉注射免疫球蛋白(IVIG)治疗诱导长期缓解。这是一名15岁男孩。移植后7周,他经历了急性排斥反应,接受了大剂量类固醇、抗胸腺细胞球蛋白(ATG)和血浆置换治疗。移植后10周(排斥反应后3周),他的血红蛋白降至54g/L,血清细小病毒B19聚合酶链反应(PCR)呈阳性。在接受IVIG治疗并将霉酚酸酯转换为雷帕霉素后,贫血得到缓解。但患者在IVIG治疗的第四天出现发热,伴有轻度肺水肿和血清肌酐升高。在第一个IVIG疗程后两个月,贫血复发,给予第二个IVIG疗程(预先给予甲泼尼龙),随后贫血缓解且无副作用,但两个月后再次复发。通过包括泼尼松龙和他克莫司在内的低剂量双重免疫抑制调整基线免疫抑制。同时,每月重复一次IVIG疗程,共进行了4次。在接下来的23个月里,贫血未复发,肾功能保持稳定。总之,细小病毒B19相关性贫血在免疫功能低下的儿童中可能会复发,应仔细调整基线免疫抑制以控制细小病毒B19感染。